Chinook Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Chinook Therapeutics (Nasdaq: KDNY) announced its upcoming participation in two major investor conferences. The company will host a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 8 at 1:20 pm EDT. Additionally, Chinook will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 at 4:50 pm EDT. Audio webcasts of these presentations will be accessible on Chinook's website for 90 days after the events. Chinook focuses on precision medicines for kidney diseases, particularly rare and severe conditions.

SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences:

• 2022 Wells Fargo Healthcare Conference – Fireside chat on Thursday, September 8^th at 1:20 pm EDT.
  
  
• Morgan Stanley 20^th Annual Global Healthcare Conference – Fireside chat on Monday, September 12^th at 4:50 pm EDT.
  

To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the Investors section of Chinook’s website. The archived audio webcasts will remain available for replay on Chinook’s website for 90 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

FAQ

When will Chinook Therapeutics participate in the 2022 Wells Fargo Healthcare Conference?

Chinook Therapeutics will participate in the 2022 Wells Fargo Healthcare Conference on September 8, 2022, at 1:20 pm EDT.

What is the date of the Morgan Stanley 20th Annual Global Healthcare Conference for Chinook?

Chinook Therapeutics is scheduled for the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 4:50 pm EDT.

Where can I find the audio webcasts of Chinook's investor presentations?

The audio webcasts for Chinook's investor presentations will be available on the Investors section of their website for 90 days.

What is Chinook Therapeutics focusing on in its drug development?

Chinook Therapeutics is focused on developing precision medicines for rare and severe kidney diseases.

What is Chinook's lead program in kidney disease treatment?

Chinook's lead program is atrasentan, a phase 3 endothelin receptor antagonist for treating IgA nephropathy and other proteinuric glomerular diseases.